Benitec Plans to Advance Lung Cancer Drug into Clinic | GenomeWeb

Benitec Biopharma this week announced that it intends to move its non-small cell lung cancer drug candidate Tribetarna into clinical trials following positive preclinical data generated in collaboration with the Children’s Cancer Institute Australia.

The company said it will use a clinical research organization to manage a planned phase I/IIa study of the expressed RNAi drug, which could begin in the fourth quarter of 2014.

Start of that trial, however, will depend on Benitec obtaining needed funding, it said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: ancient Ethiopian genome indicates greater Eurasian backflow into Africa, sequencing to diagnose cutaneous T cell lymphoma, and more.

The US House of Representatives science committee has passed a bill to require NSF to ensure it only funds projects that are in the national interest.

DuPont teams with genome editing firm Caribou Biosciences for agricultural applications of the technology.

A blogger reviews her experience learning about her gut microbiome by shipping a sample to uBiome.